<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829035</url>
  </required_header>
  <id_info>
    <org_study_id>STAH Korea Trial</org_study_id>
    <nct_id>NCT01829035</nct_id>
  </id_info>
  <brief_title>A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC</brief_title>
  <official_title>A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-center, open-labeled, phase III study in patients with advanced&#xD;
      HCC. A total of 338 patients will be randomized (1:1) into one of the two treatment arms, to&#xD;
      receive sorafenib with (Arm Combination-treatment; Arm C) or without (Arm Sorafenib alone&#xD;
      treatment; Arm S) cTACE.&#xD;
&#xD;
      All the patients will be initially given sorafenib within 72 hours after the randomization.&#xD;
      Treatment should continue until the criteria for treatment discontinuation are met.&#xD;
&#xD;
      After the treatment period, patients will undergo follow up for survival every 12 weeks (±7&#xD;
      days) from the last dose, and the survival follow up will be performed for at least 1.5 years&#xD;
      after the last patient's last treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The superiority of the Arm C (cTACE+Sorafenib) over the Arm S (Sorafenib) in the OS period&#xD;
      will be verified in the ITT set and FAS using a stratified log-rank test. Stratification&#xD;
      factors consist of mUICC stage (III vs. IV), Vascular invasion (none and Vp1-2 vs. Vp3-4 and&#xD;
      any other presence), Child-Pugh score (5 vs. 6-7), serum AFP level (≥200 ng/mL vs. &lt;200&#xD;
      ng/mL). The significance level is 5% (one-sided).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 21, 2013</start_date>
  <completion_date type="Actual">June 21, 2017</completion_date>
  <primary_completion_date type="Actual">June 21, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The overall survival (OS) of oral sorafenib given as monotherapy daily compared to sorafenib with combination cTACE in subjects</measure>
    <time_frame>3.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)in patients</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate (TRR)in patients</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)will be evaluated</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of adverse events</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">339</enrollment>
  <condition>Advanced Adult Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm S</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>sorafenib 400mg bid daily po until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after the first Conventional Transarterial Chemoembolization is completed, sorafenib po and cTACE on demand until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional Transarterial Chemoembolization (cTACE)</intervention_name>
    <description>Concurrent use of the following material/drug is defined as cTACE in this trial.&#xD;
Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil&#xD;
Anti-tumor drug:&#xD;
Unapproved drug/embolization material from each regulatory agency should not be used.&#xD;
To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be eligible to participate in the study, patients must meet the following criteria:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Clinical or histological diagnosis of HCC based on the guidelines of the Korean Liver&#xD;
             Cancer Study Group and the National Cancer Center Korea&#xD;
&#xD;
          3. At least one typical enhanced index lesion in the liver that is bi-dimensionally&#xD;
             measurable by multiphasic spiral CT scan or dynamic contrast-enhanced MRI, and size of&#xD;
             largest tumor is 15 cm or less at enrollment.&#xD;
&#xD;
          4. Tumor conditions confirmed by abdominal imaging (contrast enhanced CT ± MRI) and chest&#xD;
             imaging (CT) performed within 4 weeks prior to the treatment initiation:&#xD;
&#xD;
          5. Age of at least 20 years.&#xD;
&#xD;
          6. ECOG Performance Status of 0, 1 or 2.&#xD;
&#xD;
          7. Child-Pugh class A or B (Child-Pugh score ≤ 7).&#xD;
&#xD;
          8. Life expectancy of at least 16 weeks.&#xD;
&#xD;
          9. Adequate bone marrow, liver, and renal function as assessed by the following&#xD;
             laboratory requirements (no transfusion, no restoration), conducted within 14 days&#xD;
             prior to screening:&#xD;
&#xD;
         10. Female patients at least 1 year postmenopausal, surgically sterile or those of&#xD;
             childbearing potential must have a negative urine pregnancy test within 14 days prior&#xD;
             to the first treatment, and have to use at least one medically acceptable and&#xD;
             effective contraceptive method for the last 2 months prior to Screening Visit: methods&#xD;
             of effective contraception result in a low failure rate (i.e. less than 1% per year)&#xD;
             when used consistently and correctly such as a barrier method (implant, injectable&#xD;
             contraceptives, oral contraceptives, intrauterine contraceptive device), hormonal IUD,&#xD;
             sexual abstinence or vasectomized partner.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joong-Won Parkr, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>March 31, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>March 27, 2018</last_update_submitted>
  <last_update_submitted_qc>March 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Joong-Won Park</investigator_full_name>
    <investigator_title>Chief of Hepatology, Center for Liver Cancer</investigator_title>
  </responsible_party>
  <keyword>TACE</keyword>
  <keyword>Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

